Filgrastrim is used for:
A. NeutropeniaB. anemia
C. polycythemia
D. Neutrophilia
Ans. A.
• Filgrastrim is recombinant human
G-CSF (rHuG-CSE used to mitigate the adverse effects of anticancer drugs.
- It is a nonglycosylated peptide of 175 aminoacids.
• rHuGM-CSF has also been developed - called sargramostim.
• SargramoStim is partly glycosylated peptide of amino acids.
• Pegfilgrastrim (Pegylated filgrastrim) has much longer half life than
filgrastrim and can be used once per chemotherapy cycle.
Action
•
Action mediated via JAKIST AT pathway
• GM-CSF has broader biological actions than G
CSF. It affects early & late granulocYtiC progenitor cells, erythroid and
megakarYOcY progenitors.
• GM-CSF also stimulates T cell proliferation (together with IL-2) and causes
mobilization of peripheral blood stem cells (this property has therapeutic
significance) GCSF>GMCSF.
Toxicity:
• G-CSF is better tolerated
• G-CSF can cause bone pain (reversible on discontinuation)
• GMCSF cart lead to - fever, malaise, arthratgiaS, myalgias and a capillary
leak syndrome (characterized by pleurallpericardial effusions and peripheral
edema)
• Splenic rupture occurs rarely with G-CSF.
